IngredientsL-Glycine (commonly referred to simply as glycine) is the simplest amino acid found in nature, denoted by the symbol Gly or G, with a chemical formula of C₂H₅NO₂ and characterized by a single hydrogen atom as its side chain. Its systematic (IUPAC) name is aminoethanoic acid. Its three-letter code is GLY, its one-letter code is G, and its codons are GGU, GGC, GGA, and GGG.
Uniquely among the 20 standard amino acids, glycine does not have D- and L-stereoisomers because of its simple structure and two hydrogen atoms at the α-carbon; it is thus unique in not being optically active. Despite this, in commercial and supplemental contexts it is almost universally designated "L-glycine" to align nomenclature with other amino acids.
Glycine is a white, sweet-tasting crystalline solid, leading to its name from the Greek word glykys meaning "sweet." While the body can synthesize it, glycine is also obtained from the diet and produced industrially by chemical synthesis for use as a food additive, a nutritional supplement, and an intermediate in the manufacture of products such as the herbicide glyphosate.
Glycine is obtainable by hydrolysis of proteins. Sweet-tasting, it was among the earliest amino acids to be isolated from gelatin (1820). Especially rich sources include gelatin and silk fibroin. It is found in varying amounts in meat, especially in tough cuts like the chuck, round, and brisket, and can also be obtained from gelatin, a substance made from collagen that is added to various food products to improve consistency. Glycine is concentrated in protein-rich foods, particularly those containing collagen. Those who eat a well-rounded, protein-rich diet will likely obtain at least 1.5 to 3 grams of glycine per day.
In traditional diets, animals were used "from nose to tail," including glycine-rich parts such as connective tissue and bone marrow; these components are usually missing from the modern Western diet. Average daily dietary intake from mixed Western diets is approximately 2 grams, primarily from animal proteins.
Glycine is readily available as a dietary supplement in capsule or powder form. The powder form dissolves easily in water and has a sweet taste. Industrially, L-amino acids including glycine are produced by fermentation methods utilizing strains of microorganisms obtained from natural sources, and microorganisms are typically modified to enhance production yields. Glycine is also used in the food industry as a preservative, an antioxidant, and a browning and seasoning agent; as it has a sweet taste, it can enhance the taste of saccharin and mask the bitter aftertaste of intense sweeteners.
Glycine was discovered in 1820 by French chemist Henri Braconnot when he hydrolyzed gelatin by boiling it with sulfuric acid. He originally called it "sugar of gelatin," but French chemist Jean-Baptiste Boussingault showed in 1838 that it contained nitrogen. In 1847, American scientist Eben Norton Horsford, then a student of the German chemist Justus von Liebig, proposed the name "glycocoll"; however, the Swedish chemist Berzelius suggested the simpler current name a year later.
Glycine as an isolated compound has no traditional use in a botanical or ethnopharmacological sense; it does not derive from a medicinal plant and was not known as a distinct molecule in pre-modern medicine. However, the foods richest in glycine — particularly gelatin, bone broth, and connective tissue — have a long cross-cultural history of therapeutic preparation. In traditional diets, animals were used "from nose to tail," including glycine-rich parts such as connective tissue and bone marrow. Preparations such as long-simmered bone broths and gelatinous meat stocks were used across European, East Asian, Middle Eastern, and indigenous American food traditions for nourishment, convalescence, and joint support. These preparations were not understood in terms of glycine specifically, but the glycine content of gelatin is now recognized as a likely contributor to observed benefits.
Modern scientific use of isolated glycine as a supplement and pharmaconutrient began in earnest during the second half of the twentieth century, with clinical investigation into high-dose glycine for psychiatric conditions gaining momentum in the 1980s and 1990s.
Glycine is a conditionally essential amino acid obtained from food and synthesized in the body, primarily from L-serine. Glycine is one of several so-called nonessential amino acids for mammals; they can synthesize it from the amino acids serine and threonine and from other sources and do not require dietary sources under normal circumstances. Nevertheless, glycine deficiency has been reported due to inadequate protein intake, malnutrition, late gestation, diabetes, insulin resistance, and increased exposure to xenobiotics.
The consequences of glycine deficiency include widespread impact on metabolism, including altered synthesis of glutathione, collagen, nucleotides, and one-carbon units, impaired antioxidant defense, cytoprotection, conjugation, and neurotransmission, and increased levels of homocysteine and deoxysphingolipids. Nutritional studies have highlighted that the amount of glycine available in humans and animals is inadequate to satisfy metabolic requirements, suggesting the need for dietary glycine supplementation.
Glycine itself is the active compound; it is not a complex botanical extract. Its wide biological activity arises from multiple distinct receptor- and pathway-level mechanisms:
In the central nervous system, glycine functions as a neurotransmitter with dual properties. It is one of the major inhibitory neurotransmitters in the spinal cord and brainstem, akin to γ-aminobutyric acid (GABA). When glycine binds to inhibitory glycine receptors (chloride-channel complexes), it causes an influx of chloride ions into neurons, hyperpolarizing the cell membrane and thereby reducing neuronal excitability. This inhibitory action contributes to glycine's calming and reflex-modulating effects on the spinal cord — for example, helping regulate motor-neuron activity and muscle tone. In addition to glycine, at least two other endogenous amino acids, β-alanine and taurine, activate glycine receptors (GlyRs).
At the same time, glycine is also an obligatory co-agonist at N-methyl-D-aspartate (NMDA) receptors, a type of excitatory glutamate receptor in the brain. The activation of NMDA receptors requiring the presence of glycine is necessary for the induction of long-term potentiation (LTP), a type of synaptic plasticity which may be fundamental to learning processes. A glycine binding site in the brain has been identified and characterized as a strychnine-insensitive site associated with the NMDA receptor complex. Glycine is a positive allosteric modulator of NMDA receptors and acts at the same allosteric site as kynurenic acid but with the opposite effect.
Glycine is the most abundant amino acid in collagen, comprising approximately one-third of all amino acid residues in the repeating Gly-X-Y motif that forms the collagen triple helix. Its small size allows the tight packing required for the triple helical structure, making glycine indispensable for connective tissue integrity, skin elasticity, joint health, and bone structure. Approximately one in three amino acids in the collagen molecule is glycine, making it one of the central building blocks of collagen and the basis for structural strength from within; if there is not enough glycine, collagen synthesis can come to a standstill.
Glycine is one of three amino acids that the body uses to make glutathione, a powerful antioxidant that helps protect cells against oxidative damage caused by free radicals. Without enough glycine, the body produces less glutathione, which could negatively affect how the body handles oxidative stress over time.
Glycine can bind to specific receptors and transporters expressed in many types of cells throughout an organism to exert its effects. There have been many studies focused on the anti-inflammatory effects of glycine, including its abilities to decrease pro-inflammatory cytokines and the concentration of free fatty acids, to improve the insulin response, and to mediate other changes. However, the mechanism through which glycine acts is not entirely clear; one major pathway is that glycine exerts its anti-inflammatory effects through modulation of the expression of nuclear factor kappa B (NF-κB) in many cell types. It can modulate immune responses and reduce oxidative stress by acting on glycine-gated chloride channels in various cell types, including immune cells; this ability to mitigate inflammation and cell damage has implications for conditions such as ischemia-reperfusion injury, inflammatory diseases, and metabolic disorders.
In animal studies of acute sleep disturbance, oral administration of glycine induced non-rapid eye movement (NREM) sleep and shortened NREM sleep latency with a simultaneous decrease in core temperature. Oral and intracerebroventricular injection of glycine elevated cutaneous blood flow at the plantar surface in a dose-dependent manner, resulting in heat loss. Pretreatment with NMDA receptor antagonists but not the glycine receptor antagonist strychnine inhibited the cutaneous blood flow increase, and induction of c-Fos expression was observed in the hypothalamic nuclei, including the medial preoptic area and the suprachiasmatic nucleus shell after glycine administration.
Evidence strength: Moderate; supported by several small randomized controlled trials in humans.
It has been found that the non-essential amino acid glycine subjectively and objectively improves sleep quality in humans who have difficulty sleeping. A study evaluated the effects of glycine on daytime sleepiness, fatigue, and performance in sleep-restricted healthy subjects, with sleep restricted to 25% less than the usual sleep time for three consecutive nights. Before bedtime, 3 g of glycine or placebo were ingested; sleepiness and fatigue were evaluated using the visual analog scale (VAS), and performance was estimated by computer-based testing. In subjects given glycine, the VAS data showed a significant reduction in fatigue and a tendency toward reduced sleepiness.
A review of human clinical studies summarized that the effects of glycine supplementation on multiple health areas such as the endocrine, metabolic, nervous, cardiovascular, and immune system were studied. A total of 50 human clinical studies found on Embase, PubMed, Web of Science, and Cochrane were included in this review, 42 of which were randomised controlled trials, with 18 involving healthy populations and 34 involving diseased populations. In these studies, glycine was taken orally by the healthy and diseased populations for up to 14 days and four months respectively. Participants taking 3 grams of glycine before bedtime reported feeling more refreshed upon waking, experienced faster sleep onset, and showed improved sleep efficiency on polysomnographic measurements.
The amino acid appears to work by facilitating the drop in core body temperature necessary for sleep initiation and by modulating neurotransmitter activity in sleep-promoting brain regions. Limitations of existing sleep trials include small sample sizes, predominantly Japanese participant populations, short durations, and in some cases industry-linked funding. Independent replication in larger and more diverse populations is needed.
Evidence strength: Moderate for non-clozapine antipsychotics; contraindicated when combined with clozapine.
Clinical trials indicate that glycine site agonists of the NMDA receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics. A double-blind, placebo-controlled, 6-week crossover treatment trial with 0.8 g/kg/day glycine added to ongoing antipsychotic medication in 17 olanzapine- or risperidone-treated schizophrenia patients resulted in a significant 23% ± 8% reduction in negative symptoms; glycine treatment was well tolerated.
In a previous study, significant improvements in negative and cognitive symptoms were observed in a group of 21 schizophrenic patients receiving high-dose glycine in addition to antipsychotic treatment; glycine treatment was associated with an 8-fold increase in serum glycine levels. A significant 34% reduction in negative symptoms was observed during glycine treatment; serum antipsychotic levels were not significantly altered.
However, schizophrenia is hypothesised to result from the hypofunctioning of NMDA receptors, and several reports have particularly underscored the potential effect of glycine on the NMDA receptor in eliciting positive neurological outcomes. The interaction with clozapine is a critical exception: in a double-blind, placebo-controlled study, 19 patients with chronic, treatment-resistant schizophrenia who were maintained on optimal doses of clozapine (400–1200 mg/day) were administered either 30 g/day of glycine or placebo for 12 weeks; the use of glycine as an adjunct to clozapine was not effective in decreasing positive or negative symptoms, while patients treated with clozapine without glycine had a 35% reduction in positive symptoms. These preliminary data suggest that glycine may interfere with the antipsychotic efficacy of atypical neuroleptics such as clozapine.
These data, combined with data from previous trials with D-cycloserine and glycine, suggest that agonists at the glycine site may be less effective when combined with clozapine than they are when combined with conventional antipsychotics. Overall, the schizophrenia evidence base is clinically interesting but consists of relatively small trials, and optimal dosing strategies and patient selection require further study.
Evidence strength: Preliminary to moderate; mostly small human trials and mechanistic studies.
A review concluded that glycine supplementation improves various components of metabolic syndrome including diabetes, obesity, hyperlipidemia, and hypertension, and that in the future, the use of glycine may have a significant clinical impact on the treatment of patients with metabolic syndrome.
In healthy populations, 5 out of 5 studies reported changes in the endocrine and metabolic system where a single oral glycine bolus improved insulin responses and increased circulating concentrations of glucagon and growth hormone. In a non-obese healthy population, an inconclusive dose-dependent outcome was observed when a single intravenous administration of 4 g glycine increased serum growth hormone concentrations, while 12 g glycine increased serum blood sugar levels. In diseased populations, oral glycine administration of 5 g × 3/day over 3 months showed positive effects in type 2 diabetes mellitus patients, including decreased glycosylated haemoglobin.
It is important to note that the overall evidence base consists of small trials with variable methodology, and well-controlled studies in subjects without glycine deficit are required to examine the potential benefits of high doses of glycine as a pharmaconutrient.
Evidence strength: Predominantly preclinical (animal and cell-based); limited direct human evidence for most anti-inflammatory claims.
Glycine effectively protects against alcohol-induced hepatotoxicity by reducing blood alcohol levels and the metabolic products of alcohol, reducing liver damage, and lowering the gastric emptying rate of ethanol. Kupffer cells increase intracellular Ca²⁺ and release prostanoids and inflammatory cytokines in response to LPS stimuli; glycine acts by preventing increases in intracellular levels of Ca²⁺ in this kind of cell. Glycine has been shown to blunt endotoxin-induced superoxide and proinflammatory cytokine TNF-α production in alveolar macrophages, and has been further shown to have anti-inflammatory and protective roles in experimental models of acute pancreatitis, gastric ulcer, and arthritis.
These findings are predominantly in rodent models. Human clinical data specifically assessing glycine as an anti-inflammatory agent are more limited and largely indirect (e.g., through metabolic syndrome trials).
Evidence strength: Indirect; clinical trials use collagen peptides (glycine-rich), not isolated glycine.
Collagen is a source of conditionally essential amino acids (glycine and proline), which are important in some physiological situations. Collagen hydrolysates present as a mix of specific peptides with a high abundance of the amino acids hydroxyproline, glycine, and proline, produced by enzymatic hydrolysis of native collagen extracted from animal connective tissues.
Regarding orthopedic changes, collagen supplementation increases bone strength, density, and mass; improves joint stiffness/mobility and functionality. A direct anti-inflammatory potential of collagen peptides can decrease joint pain intensity, since collagen peptide supplementation inhibits glycine-mediated cytokine release. However, these clinical trials test hydrolyzed collagen peptides as a whole, and it is not possible to isolate the specific contribution of glycine versus proline or other constituents from these data.
Evidence strength: Preliminary; a small number of crossover trials.
Improved psychiatric symptoms in populations afflicted with psychiatric diseases were accompanied by improved cognition and extrapyramidal symptoms. In the sleep-restriction crossover trial discussed above, subjects given glycine showed a significant reduction in fatigue and a tendency toward reduced sleepiness on the visual analog scale. These findings, while consistent, are drawn from small, primarily Japanese samples.
Evidence strength: Preclinical; limited human data.
Acid secretions caused by pylorus ligation are decreased by glycine. Glycine also protects against experimental gastric lesions in rats caused by indomethacin, hypothermic-restraint stress, and necrotizing agents. Glycine possesses effective cytoprotective and antiulcer activity. In rats injected with PG-PS which suffer from infiltration of inflammatory cells, synovial hyperplasia, edema, and ankle swelling, 2 days of oral glycine supplementation after TNBS administration was very effective in lowering inflammation, showing therapeutic and prophylactic benefits. These findings remain animal-based, and direct human clinical trials are lacking.
Glycine is readily available as a dietary supplement in capsule or powder form; the powder dissolves easily in water.
The following dosages have been used in published scientific studies:
It is estimated that we get about 2 grams of glycine a day from food sources. Optimal therapeutic doses for glycine have not been set for any condition.
Glycine supplements are generally well-tolerated. At typical supplemental doses of 3–5 g/day, no serious side effects have been reported. No serious adverse effects from using glycine have been reported, even at doses as high as 60 g per day. Side effects are rare at typical supplemental doses. When they occur, they may include gastrointestinal effects such as stomach pain, nausea, and diarrhea (reported rarely at standard doses, more common at high doses), as well as nausea and vomiting when taken in very high doses over 40 g/day, and paradoxical irritability and insomnia.
Clozapine is used to help treat schizophrenia. Taking glycine along with clozapine might decrease the effectiveness of clozapine, though it is not clear why this interaction occurs. This is the most clinically significant drug interaction identified in human research. Preliminary data suggest that glycine may interfere with the antipsychotic efficacy of atypical neuroleptics such as clozapine.
Glycine may interact with medicines for seizures (such as carbamazepine, phenobarbital, or valproic acid), clozapine, and memantine (used for dementia). As with most dietary supplements, the research on drug interactions with glycine is incomplete.
Glycine deficiency has been reported due to inadequate protein intake, malnutrition, late gestation, diabetes, insulin resistance, and increased exposure to xenobiotics. Rather than glycine alone, its coadministration with L-serine may be more appropriate in glycine-deficient conditions, as the close metabolic links between the two amino acids mean that isolated high-dose glycine supplementation could affect one-carbon metabolism.
Theoretical concerns have been raised suggesting that glycine might increase brain injury in strokes. Drugs that block glycine have been investigated as treatments to limit stroke damage; however, the authors of some stroke studies make an argument suggesting that glycine's overall effect is protective. The net effect of exogenous glycine in acute stroke remains an area of active scientific debate.
Several small clinical trials, generally supported by Ajinomoto (a major glycine manufacturer), have evaluated glycine supplementation for improving sleep quality, reducing nighttime urinary frequency, and improving symptoms in schizophrenia. Commercial sponsorship is a recognized potential source of bias in interpreting positive results from the sleep research literature. Well-controlled studies in subjects without glycine deficit are required to examine the potential benefits of high doses of glycine as a pharmaconutrient.
Health conditions that L-glycine may help support.
Glycine is an obligate precursor for glutathione (GSH), the most abundant intracellular antioxidant and a key molecule in cellular detoxification and redox regulation. GlyNAC clinical trials demonstrate that glycine supplementation restores GSH deficiency and corrects oxidative stress in older adults, HIV patients, and metabolic disease states.
Clinical trials show that 3 g of glycine taken before bedtime significantly reduces self-reported anxiety levels the following morning. Glycine acts as an inhibitory neurotransmitter, dampening neural excitability via strychnine-insensitive glycine receptors. Evidence comes from small controlled studies in individuals with poor sleep and insomniac tendencies.
Glycine is essential for the synthesis of type II collagen, the major structural protein in articular cartilage degraded in arthritis. It also reduces pro-inflammatory cytokine production (TNF-alpha, IL-6) and NF-κB activation, which drive synovial inflammation. Clinical trials of glycine-rich collagen peptides show improvements in joint pain and function in osteoarthritis patients.
Clinical trials in metabolic syndrome patients show that glycine supplementation at 5–15 g/day reduces systolic blood pressure. The GlyNAC 16-week RCT in older adults also documented improvement in blood pressure alongside other aging-related defects. Mechanistically, glycine improves endothelial function and reduces vascular inflammation.
Lower circulating glycine is consistently observed in type 2 diabetes and obesity, and clinical trials suggest glycine supplementation can improve fasting glucose and postprandial glycemic control. A 5 g oral dose has been shown to increase insulin secretory responses, and RCT evidence supports modest reductions in HbA1c in metabolic syndrome patients. Effects are adjunctive rather than pharmacological.
Glycine is an established inhibitory neurotransmitter in the spinal cord and brainstem, and its ingestion promotes subjective feelings of calm and relaxation. Human clinical studies using 3 g before bedtime report reduced daytime fatigue and improved tranquility scores. The mechanism involves both glycine receptor-mediated neuronal inhibition and reductions in core body temperature.
Glycine constitutes approximately one-third of all amino acid residues in collagen, which forms the structural matrix of cartilage. Adequate glycine is rate-limiting for collagen synthesis, and deficiency impairs maximal collagen production. While most direct evidence comes from biochemical and in vitro work, clinical trials of collagen peptides (which are glycine-rich) support cartilage and joint matrix support.
Glycine supports cellular energy through multiple pathways: it contributes to mitochondrial glutathione that protects respiratory chain function, participates in creatine synthesis (with arginine) for phosphocreatine energy buffering, and is a substrate in the glycine cleavage system that feeds one-carbon units into folate metabolism used in ATP production. GlyNAC RCTs demonstrate correction of mitochondrial fuel oxidation.
Glycine inhibits pro-inflammatory cytokine production including TNF-alpha and IL-6 and suppresses NF-κB pathway activation. GlyNAC (glycine + N-acetylcysteine) RCT evidence in older adults demonstrates significant reduction in inflammatory markers. Glycine also modulates Kupffer cell and macrophage activity in the liver, reducing inflammatory responses.
GlyNAC supplementation in multiple clinical trials in older adults demonstrates significant improvements in cognitive function, including Montreal Cognitive Assessment (MoCA) scores, alongside reversal of oxidative stress, mitochondrial dysfunction, and inflammation that drive age-related cognitive decline. Glycine's role as an NMDA co-agonist further supports synaptic plasticity relevant to cognitive aging.
Glycine is the most abundant amino acid in collagen (approximately one-third of all collagen residues) and is required as every third amino acid in the Gly-X-Y triplet repeat that forms the collagen triple helix. Supplemental glycine supports collagen synthesis in all connective tissues and has been used in wound healing and recovery protocols.
Oral glycine administration acutely stimulates pituitary growth hormone (GH) secretion in a dose-dependent manner. A bolus of 22.5 g has been reported to cause a ~60% surge in GH levels within minutes. Smaller doses of 4–12 g also raise serum GH in a dose-dependent fashion, per early pharmacological studies.
GlyNAC (glycine + N-acetylcysteine) supplementation in multiple RCTs in older adults corrects glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, and insulin resistance—all hallmarks of aging. These trials show measurable improvements in physical function, muscle strength, and cognitive performance. Collagen-amino acid ratio supplementation containing glycine also reduced biological age in a clinical observational trial.
Multiple controlled clinical trials demonstrate that 3 g of oral glycine before bedtime improves both subjective and objective sleep quality in individuals with insomnia or insomniac tendencies. Polysomnographic studies confirm reduced sleep onset latency, shorter time to slow-wave sleep, and improved sleep efficiency. The mechanism involves peripheral vasodilation causing a drop in core body temperature that facilitates sleep initiation.
Low plasma glycine is a robust biomarker of insulin resistance, and multiple clinical studies show glycine supplementation improves insulin secretion, sensitivity, and postprandial glucose control. GlyNAC RCTs also demonstrate correction of insulin resistance in older adults. Mechanistically, glycine may enhance GLP-1 secretion and improve pancreatic beta-cell function.
L-glycine is the supplemental form of glycine, an amino acid with documented anti-inflammatory effects on intestinal epithelial cells and essential roles in glutathione synthesis and collagen/ECM production for gut lining integrity. Authoritative leaky gut ingredient reviews identify glycine-related amino acids as critical for gut healing, and glycine is included in evidence-based gut-healing amino acid protocols alongside glutamine and proline.
Glycine is a direct precursor of glutathione (γ-L-glutamyl-L-cysteinyl-glycine), the liver's principal endogenous detoxification antioxidant. Glycine also participates directly in hepatic phase II conjugation (glycine conjugation), detoxifying bile acids and aromatic compounds. Animal studies show hepatoprotective effects, and small clinical trials suggest benefit in chronic hepatitis and fatty liver disease.
Glycine is an obligate co-agonist at NMDA receptors, which are central to synaptic plasticity and memory consolidation. Clinical RCTs with GlyNAC in older adults show measurable improvements in cognitive function including memory. Glycine sleep studies also document improvements in memory recognition tasks the morning after supplementation.
Plasma glycine is consistently lower in metabolic syndrome patients than in healthy controls. A published review of clinical and preclinical evidence concludes that glycine supplementation improves multiple components of metabolic syndrome including hyperglycemia, hypertension, hyperlipidemia, and obesity-related inflammation. RCTs document reductions in HbA1c, CRP, and blood pressure.
GlyNAC supplementation (glycine + N-acetylcysteine) has demonstrated in controlled clinical trials that it corrects mitochondrial fuel oxidation defects in older adults. Glycine's role as a glutathione precursor is central: GSH deficiency impairs mitochondrial function, and restoring GSH via GlyNAC reverses mitochondrial dysfunction. Multiple RCTs confirm improvements in mitochondrial fatty-acid oxidation.
Glycine contributes to muscle recovery by suppressing proteolytic gene expression, activating anabolic signaling pathways (Akt-mTOR-FOXO1), and reducing post-exercise inflammation via inhibition of NF-κB and pro-inflammatory cytokines. It also contributes to creatine synthesis via arginine-glycine amidinotransferase. Evidence is primarily from cell and animal studies, with limited human RCT data.
Glycine is itself a major inhibitory neurotransmitter in the spinal cord and brainstem, activating strychnine-sensitive glycine receptors (GlyRs). It is also an obligate co-agonist at excitatory NMDA glutamate receptors, making it unique in modulating both inhibitory and excitatory neurotransmission. High-dose glycine clinical trials have demonstrated restoration of NMDA receptor function in schizophrenia patients.
L-Glycine is the most abundant amino acid in collagen and is essential for wound healing, tissue protection, and immunity post-surgically. Scientific reviews confirm glycine contributes to protein synthesis, wound repair, and immune response. Collagen peptides rich in glycine have demonstrated clinical benefits in multiple post-surgical healing trials.
Glycine is a primary structural amino acid in collagen, required for postpartum wound healing and tissue repair. A US patent on postpartum recovery formulas specifically cites glycine (alongside proline and vitamin C) as a collagen-supporting nutrient for postpartum wound healing and connective tissue restoration. It is included in expert postnatal formulas for this purpose.
Glycine is the most abundant amino acid in skin collagen (approximately one-third of all residues) and is rate-limiting for collagen synthesis. Clinical trials of glycine-rich collagen peptide supplements show significant reductions in wrinkle depth, improved skin hydration, and increased elasticity. A collagen amino acid composition containing glycine also reduced biological skin age in a controlled observational trial.
Glycine is the most abundant amino acid in collagen (~33% of residues, occupying every third position in the Gly-X-Y repeat). In dermal fibroblasts, glycine is superior to proline, glutamine, and leucine at increasing collagen synthesis. A 2025 in vivo study showed atelocollagen enhanced collagen synthesis in aged mouse skin through GlyT1-dependent glycine transport, increasing collagen density and skin elasticity.
Controlled clinical trials and polysomnographic studies demonstrate that 3 g of glycine before bedtime shortens sleep onset latency and reduces time to slow-wave sleep. The mechanism involves NMDA receptor-mediated activation in the suprachiasmatic nucleus, inducing peripheral vasodilation and a drop in core body temperature that facilitates rapid sleep initiation.
Glycine is a non-essential amino acid that subjectively and objectively improves sleep quality in individuals with insomnia or restricted sleep. Human RCTs at 3 g before bedtime found improved PSQI scores, reduced sleep latency, increased slow-wave sleep, and reduced daytime fatigue. The mechanism involves NMDA receptor modulation in the suprachiasmatic nucleus causing peripheral vasodilation and body temperature lowering, which promotes sleep onset.
A PubMed review of glycine's effects on metabolic syndrome components concludes that glycine supplementation improves hyperlipidemia, including elevated triglycerides, alongside other components of metabolic syndrome. Lower plasma glycine is consistently found in metabolic syndrome patients, and supplementation partially reverses this defect.
Glycine is an obligate structural component of collagen (one-third of residues), which is essential for wound closure and tissue remodeling. In vitro, glycine enhances collagen production in human dermal fibroblasts. Animal and human clinical evidence with collagen-based interventions supports accelerated wound healing, reduced infection, and better tissue regeneration.
Body systems that L-glycine may help support.
Go back